| Předmět: |
|
| Zdroj: |
Blood Weekly; 5/20/2024, p402-402, 1p |
| Abstrakt: |
A recent study conducted by researchers at the National Cancer Institute (NCI) explored the immunologic mechanisms underlying the use of posttransplantation cyclophosphamide (PTCy) in reducing graft-versus-host disease (GVHD) after allogeneic hematopoietic cell transplantation (HCT). The study found that PTCy induces suppressive mechanisms that prevent GVHD induction by new donor cells. The researchers hypothesized that myeloid-derived suppressor cells (MDSCs) play a complementary role in controlling GVHD. They observed an increase in functionally suppressive MDSCs in PTCy-treated mice and patients undergoing HCT. The study suggests that further investigation is needed to understand the clinical implications of these findings and the indirect effect of PTCy on regulatory T cells (Tregs) in preventing GVHD. [Extracted from the article] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
